Research advances from the National Institutes of Health (NIH) Intramural Research Program (IRP) often make headlines. Read the news releases that describe our most recent findings:
BETHESDA, Md. (AP) — Sam Srisatta, a 20-year-old Florida college student, spent a month living inside a government hospital here last fall, playing video games and allowing scientists to document every morsel of food that went into his mouth.
From big bowls of salad to platters of meatballs and spaghetti sauce, Srisatta noshed his way through a nutrition study aimed at understanding the health effects of ultraprocessed foods, the controversial fare that now accounts for more than 70% of the U.S. food supply. He allowed The Associated Press to tag along for a day.
“Today my lunch was chicken nuggets, some chips, some ketchup,” said Srisatta, one of three dozen participants paid $5,000 each to devote 28 days of their lives to science. “It was pretty fulfilling.”
Examining exactly what made those nuggets so satisfying is the goal of the widely anticipated research led by National Institutes of Health nutrition researcher Kevin Hall.
“What we hope to do is figure out what those mechanisms are so that we can better understand that process,” Hall said.
NIH trial shows new form of TIL therapy effective against colon, rectum, pancreas, and bile duct tumors
A new form of tumor infiltrating lymphocyte (TIL) therapy, a form of personalized cancer immunotherapy, dramatically improved the treatment’s effectiveness in patients with metastatic gastrointestinal cancers, according to results of a clinical trial led by researchers at the National Institutes of Health (NIH). The findings, published April 1, 2025 in Nature Medicine, offer hope that this therapy could be used to treat a variety of solid tumors, which has so far eluded researchers developing cell-based therapies.
This form of therapy involves identifying and selecting immune cells (TILs) that are found in the tumor that specifically recognize and attack a patient’s tumor cells. Next, scientists grow those TILs into large quantities in the laboratory before they are finally administered to the patient.
Patients in the clinical trial, who had a variety of gastrointestinal tumors, also received the immune checkpoint inhibitor pembrolizumab (Keytruda) to help further boost their immune response. The result was nearly 24 percent of patients treated with selected TILs plus pembrolizumab had a substantial reduction in the size of their tumors, compared with 7.7 percent of patients who received selected TILs without pembrolizumab. Patients treated with TILs that had not been selected for anti-tumor activity had no tumor shrinkage.
“We're seeing the first extension of cellular therapy with TILs into the common solid cancers,” said Steven A. Rosenberg, M.D., Ph.D., the study’s lead investigator at NIH’s National Cancer Institute. “We see a little crack in the solid wall of cancer by using cell-based immunotherapy for the common solid cancers, and we think we have ways to open that crack even further.”
Image of an MRI scan showing shrinkage of multiple liver metastases from a patient with rectal cancer
Jayanta “Jay” Bhattacharya, M.D., Ph.D., took office today as the 18th Director of the National Institutes of Health (NIH). President Trump nominated Dr. Bhattacharya for the position on Nov. 26, 2024, and the U.S. Senate confirmed him on March 25, 2025.
As Director, Dr. Bhattacharya will oversee the nation’s medical research agency. Dr. Bhattacharya will play an instrumental role in shaping the agency’s activities and outlook and ensuring they align with the President’s Make America Healthy Again Commission.
"Under Dr. Bhattacharya’s leadership, NIH will restore its commitment to gold-standard science,” said HHS Secretary Robert F. Kennedy, Jr. “I’m excited to work with Dr. Bhattacharya to ensure NIH research aligns with our Administration’s priorities — especially tackling the chronic disease epidemic and helping to Make America Healthy Again.”
“Chronic diseases such as cancer, heart disease, diabetes and obesity continue to cause poor health outcomes in every community across the United States. Novel biomedical discoveries that enhance health and lengthen life are more vital than ever to our country’s future,” said Dr. Bhattacharya. “As NIH Director, I will build on the agency’s long and illustrious history of supporting breakthroughs in biology and medicine by fostering gold-standard research and innovation to address the chronic disease crisis.”
NIH study finds number of steps taken daily may be more important for cancer risk than the intensity of activity
In a prospective cohort study of more than 85,000 adults in the United Kingdom, researchers at the National Institutes of Health (NIH) and University of Oxford found that individuals who engaged in light- and moderate-to-vigorous-intensity daily physical activity had a lower risk of cancer than individuals who were more sedentary. The findings, published March 26, 2025, in British Journal of Sports Medicine, are among the first to evaluate the cancer risk reduction associated with light intensity activities such as doing errands and performing household chores.
Previous studies have shown an inverse association between physical activity and cancer risk, but most of these studies relied on self-reported questionnaires, which may not accurately capture the intensity of different activities. Earlier studies that used objective measures were focused on higher-intensity physical activity. In the new study, led by researchers from NIH’s National Cancer Institute, participants in the UK Biobank study (median age of 63) wore wrist accelerometers that tracked total daily activity, activity intensity, and daily step count over a period of one week. The researchers then looked at the relationship between the daily averages and incidence of 13 cancer types, including breast and colorectal cancer, previously associated with physical activity.
After a mean follow-up of 5.8 years, 2,633 participants had been diagnosed with one of the 13 cancer types. Individuals with the highest total amount of daily physical activity had a 26 percent lower risk of developing cancer than individuals who had the lowest amount of daily physical activity. The researchers also explored the impact of replacing daily sedentary time with light- and moderate-to-vigorous-intensity physical activity and found that this shift was associated with a reduced risk of cancer. The associations between physical activity and cancer risk remained even after researchers adjusted for demographic factors, lifestyle factors, body mass index (BMI), and other health conditions.
Treatment shows potential to slow the progression of human degenerative eye diseases, including retinitis pigmentosa
Researchers at the National Institutes of Health (NIH) have developed eye drops that extend vision in animal models of a group of inherited diseases that lead to progressive vision loss in humans, known as retinitis pigmentosa. The eye drops contain a small fragment derived from a protein made by the body and found in the eye, known as pigment epithelium-derived factor (PEDF). PEDF helps preserve cells in the eye’s retina. A report on the study is published in Communications Medicine.
“While not a cure, this study shows that PEDF-based eye drops can slow progression of a variety of degenerative retinal diseases in animals, including various types of retinitis pigmentosa and dry age-related macular degeneration (AMD),” said Patricia Becerra, Ph.D., chief of NIH’s Section on Protein Structure and Function at the National Eye Institute and senior author of the study. “Given these results, we’re excited to begin trials of these eye drops in people.”
Model of PEDF protein alongside the smaller, modified versions of it used in the IRP study.
Researchers at the National Institutes of Health (NIH) have determined that dermatitis resulting from topical steroid withdrawal (TSW) is distinct from eczema and is caused by an excess of an essential chemical compound in the body. Scientists from NIH’s National Institute of Allergy and Infectious Diseases (NIAID) identified treatments that could be studied in clinical trials for the condition based on their potential to lower levels of the chemical compound — called nicotinamide adenine dinucleotide (NAD+), a form of vitamin B3. The findings were published today in the Journal of Investigative Dermatology.
Dermatitis is characterized by inflammation, itching, or burning sensations on the skin, and can result from various conditions including TSW and eczema. Eczema, also known as atopic dermatitis, is a common cause of dermatitis and affects 10 to 30% of children and 2 to 10% of adults each year in the United States. Topical steroids — specifically glucocorticoids or topical corticosteroids — have long been used as a first-line treatment for dermatitis caused by eczema because the drugs are safe, effective, easy to apply, and considered well-tolerated.
Some people experience dermatitis after using topical steroids for prolonged periods of time and then stopping — a condition called TSW. Diagnosing and treating this condition is difficult because TSW is not well understood. Symptoms include skin redness, burning sensations, skin heat (thermal dysregulation), itching and peeling, which can even occur on parts of the body where topical steroids were not applied. As TSW and eczema have similar symptoms, it has been difficult to distinguish the two disorders.
Hand and wrist of a participant in the pilot study before (left) and after (right) treatment of topical steroid withdrawal symptoms with berberine, a mitochondrial complex I-blocking drug.
NIH study reveals key players underlying disease onset and repair
Using an animal model of multiple sclerosis (MS), researchers at the National Institutes of Health (NIH) have created a four-dimensional brain map that reveals how lesions similar to those seen in human MS form. These findings, published in Science, provide a window into the early disease state and could help identify potential targets for MS treatments and brain tissue repair.
The researchers, led by postdoctoral fellow Jing-Ping Lin, Ph.D., and senior investigator Daniel S. Reich, M.D., Ph.D., both at NIH’s National Institute of Neurological Disorders and Stroke (NINDS), combined repeated MRI imaging with brain-tissue analysis, including gene expression, to track the onset and development of MS-like lesions. They uncovered a new MRI signature that can help detect brain regions at risk for damage weeks before any visible lesions occur. They also identified “microenvironments” within affected brain tissue based on observed patterns of neural function, inflammation, immune and support cell responses, gene expression, and levels of damage and repair.
“Identifying the early events that occur after inflammation and teasing apart which are reparative versus which are damaging, can potentially help us identify MS disease activity sooner and develop treatments to slow or stop its progression,” said Dr. Reich.
NIH science lays groundwork for future studies in people
National Institutes of Health (NIH) scientists and their colleagues report that a single dose of a broadly neutralizing antibody (bnAb) administered prior to virus exposure protects macaques from severe H5N1 avian influenza. Highly pathogenic avian influenza (HPAI) H5N1 viruses have sporadically spilled over from birds into many other animals, including humans and dairy cows, in recent years. Although it has not yet acquired the capacity to spread readily between people, H5N1 has pandemic potential, which has spurred efforts to develop effective treatments and other countermeasures.
The investigators studied a bnAb called MEDI8852, which was discovered and developed by Medimmune, now part of AstraZeneca. MEDI8852 targets a portion of a key flu protein that is less prone to change than other parts of the virus and thus is capable of conferring protection against a wide range of flu viruses. In the new study, a group of macaques received an injection of MEDI8852 and were exposed to aerosolized HPAI H5N1 virus three days later. All the pre-treated animals survived and experienced no or very limited signs of disease. In contrast, a group of control macaques developed severe or fatal illness within a short time after virus exposure. Of note, the scientists determined that MEDI8852 remained in the body for a prolonged time after the injection. According to scientists, protection from severe disease would extend to weeks beyond antibody infusion, providing a realistic preventative window in the face of an H5N1 outbreak.
Three influenza A (H5N1/bird flu) virus particles (rod-shaped). Note: Layout incorporates two CDC transmission electron micrographs that have been inverted, repositioned, and colorized by NIAID. Scale has been modified.
NIH study identifies previously unknown adaptation
Influenza A virus particles strategically adapt their shape—to become either spheres or larger filaments — to favor their ability to infect cells depending on environmental conditions, according to a new study from National Institutes of Health (NIH) scientists. This previously unrecognized response could help explain how influenza A and other viruses persist in populations, evade immune responses, and acquire adaptive mutations, the researchers explain in a new study published in Nature Microbiology.
The study, led by intramural researchers at NIH’s National Institute of Allergy and Infectious Diseases (NIAID), was designed to determine why many influenza A virus particles exist as filaments. The filament shape requires more energy to form than a sphere, they state, and its abundance has been previously unexplained. To find the answer, they developed a way to observe and measure real-time influenza A virus structure during formation.
Colorized transmission electron micrograph of influenza A virus particles, colorized red and gold, isolated from a patient sample and then propagated in cell culture.
Findings from NIH study suggest early intervention may prevent adult obesity associated with heavier birthweight
Fetuses of pregnant people who gained excess weight in the first trimester of pregnancy show signs of excess fat distribution in the upper arm and in the abdomen, according to a study by researchers at the National Institutes of Health (NIH). These findings may inform efforts to prevent excessive weight gain early in life, a risk factor for adult obesity and related conditions, such as heart disease, high blood pressure and diabetes. The study, conducted by researchers at NIH’s Eunice Kennedy Shriver National Institute of Child Health and Human Development and other institutions, appears in the American Journal of Clinical Nutrition.
The authors analyzed data from an earlier study of more than 2,600 singleton pregnancies, which included information on maternal weight before and during pregnancy and three-dimensional (3D) ultrasound scans (up to five) throughout pregnancy. The authors found that pregnant people with excessive weight gain — defined as more than 2 kilograms (about 4.4 pounds) in the first trimester — had fetuses with larger abdominal circumference and abdominal area and larger fetal arm fat thickness, when compared to pregnant people with adequate weight gain. Fetuses from the excessive weight gain group continued to have greater arm thickness and abdominal measurements through the end of pregnancy, even when weight gain was not considered excessive during the second and third trimesters. In contrast, most previous studies have not examined fetal 3D measures during pregnancy and have only linked total weight gain across pregnancy, not just in the first trimester, with birthweight.
New antibodies could lead to next generation of interventions against malaria
A novel class of antibodies that binds to a previously untargeted portion of the malaria parasite could lead to new prevention methods, according to a study from researchers at the National Institutes of Health (NIH) published today in Science. The most potent of the new antibodies was found to provide protection against malaria parasites in an animal model. The researchers say antibodies in this class are particularly promising because they bind to regions of the malaria parasite not included in current malaria vaccines, providing a potential new tool for fighting this dangerous disease.
Malaria is a life-threatening disease caused by Plasmodium parasites, which are spread through the bites of infected mosquitoes. Although malaria is not common in the United States, its global impact is devastating, with 263 million cases and 597,000 deaths estimated by the World Health Organization in 2023. Of the five species of Plasmodium that cause malaria, Plasmodium falciparum is the most common in African countries where the burden of malaria is largest and where young children account for the majority of malaria deaths. Safe and effective countermeasures are critical for reducing the immense burden of this disease.
In recent years, new interventions have been developed against malaria, including vaccines that currently are being rolled out for young children in regions where the disease is prevalent. Anti-malarial monoclonal antibodies (mAbs) are another promising new tool that have been shown to be safe and efficacious against infection with P. falciparum in adults and children in early clinical trials. The anti-malarial mAbs evaluated in trials in malaria-endemic regions target the P. falciparum sporozoite — the life stage of the parasite that is transmitted from mosquitoes to people. By binding to and neutralizing the sporozoite, the mAbs prevent sporozoites from infecting the liver, where they otherwise develop into blood-stage parasites that infect blood cells and cause disease and death.
Colorized scanning electron micrograph of red blood cell infected with malaria parasites (orange/red/yellow). The small bumps on the infected cell show how the parasite remodels its host cell by forming protrusions called 'knobs' on the surface, enabling it to avoid destruction and cause inflammation. Uninfected cells (teal) have smoother surfaces.
